^
Association details:
Evidence:
Evidence Level:
Sensitive: B - Late Trials
Title:

Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial

Published date:
07/26/2021
Excerpt:
Patients with previously treated CLL with centrally confirmed del(17)(p13.1) or del(11)(q22.3) were randomly assigned to oral acalabrutinib...After a median follow-up of 40.9 months, acalabrutinib was determined to be noninferior to ibrutinib with a median PFS of 38.4 months in both arms...
DOI:
10.1200/JCO.21.01210
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results

Published date:
04/09/2020
Excerpt:
In this phase 1b/2 study, 134 patients with relapsed/refractory CLL or SLL (median age, 66 years [range, 42-85 years]; median prior therapies, 2 [range, 1-13]) received acalabrutinib...responses were similar regardless of genomic features (presence of del(11)(q22.3), del(17)(p13.1), complex karyotype, or immunoglobulin variable region heavy chain mutation status).
DOI:
10.1182/blood.2018884940
Trial ID: